v3.25.2
Earnings per Share/Capital Stock (Tables)
 6 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
Schedule of reconciliation of Registrant's net income and weighted average Common Shares outstanding for calculating basic net income per share
The following is a reconciliation of Registrant’s net income and weighted average Common Shares outstanding used to calculate basic EPS:
Basic: For The Three Months Ended 
 June 30,		 For The Six Months Ended 
 June 30,
(in thousands, except per share amounts)2025202420252024
Net income$33,690 $31,864 $60,534 $54,999 
Less: impact from participating securities135 110 213 162 
Total income available to common shareholders$33,555 $31,754 $60,321 $54,837 
Weighted average Common Shares outstanding, basic38,509 37,309 38,382 37,169 
Basic earnings per Common Share$0.87 $0.85 $1.57 $1.48 
Schedule of reconciliation of Registrant's net income and weighted average Common Shares outstanding for calculating diluted net income per share
The following is a reconciliation of Registrant’s net income and weighted average Common Shares outstanding used to calculate diluted EPS:
Diluted: For The Three Months Ended 
 June 30,		 For The Six Months Ended 
 June 30,
(in thousands, except per share amounts)2025202420252024
Common shareholders earnings, basic$33,555 $31,754 $60,321 $54,837 
Undistributed earnings for dilutive restricted stock units
63 54 87 67 
Total common shareholders earnings, diluted$33,618 $31,808 $60,408 $54,904 
Weighted average Common Shares outstanding, basic38,509 37,309 38,382 37,169 
Stock-based compensation (1)
133 109 118 94 
Weighted average Common Shares outstanding, diluted38,642 37,418 38,500 37,263 
Diluted earnings per Common Share$0.87 $0.85 $1.57 $1.47 
(1)     In applying the treasury stock method of reflecting the dilutive effect of outstanding stock-based compensation in calculating diluted EPS, 158,549 and 132,530 restricted stock units, including performance awards to officers of the Company at June 30, 2025 and 2024, respectively, were deemed to be outstanding and included in the calculation of diluted EPS.